-
Federal Trade Commission Targets 'Junk Patent Listings' For Diabetes, Weight Loss, Asthma Drugs From Companies Like Novo Nordisk, AstraZeneca
Wednesday, May 1, 2024 - 4:11pm | 650Read More...The Federal Trade Commission (FTC) is intensifying its efforts to challenge numerous pharmaceutical patent listings, aiming to facilitate the availability of more affordable alternatives to brand-name drugs, including blockbusters like Novo Nordisk A/S’s (NYSE:NVO) Ozempic...
-
FDA Issues Final Guidelines To Make Interchangeable Biosimilars More Easily Available
Monday, May 13, 2019 - 2:15pm | 424Read More...The FDA issued final guidelines Friday concerning the interchangeability of biosimilars with biologics with an intention to make the former easily available to patients, just as how generics are used for branded drugs. What Happened The FDA's latest guidelines outlined the studies a...
-
Recro's Late-Stage IV Meloxicam Trial Results Rocket Stock Skyward
Monday, November 28, 2016 - 11:42am | 368Read More...Recro Pharma Inc (NASDAQ: REPH) shares are jumping on Monday after it announced positive top-line results from the second of the two late-stage trials of intra-venous meloxicam meant to treat acute post-operative pain. The Compound Meloxicam is long-acting preferential COX-2 inhibitor,...
-
AbbVie Says Risankizumab More Effective Than Placebo For Crohn's Disease Management
Tuesday, May 24, 2016 - 12:14pm | 379Read More...AbbVie Inc (NYSE: ABBV) disclosed that it presented a proof of concept, Phase II trial in Crohn's disease with investigatory biologic risankizumab, a compound from Boehringer Ingelheim research and recently licensed by the company. According to the company, Risankizumab was shown to be more...
-
Perrigo Surges Amid Report Of Omega Pharma Acquisition
Thursday, October 30, 2014 - 11:17am | 301Read More...Shares of Perrigo Company plc (NYSE: PRGO) surged higher Thursday amid reports that the company will buy Omega Pharma NV. Bloomberg reported that "Perrigo Co. has entered exclusive talks to buy Omega Pharma NV after beating suitors including Sanofi, Actavis Plc and Boehringer Ingelheim...
-
Piper Jaffray Comments on Gilead Sciences' Licensing Agreement with Boehringer Ingelheim
Thursday, October 6, 2011 - 11:32am | 155Read More...Piper Jaffray has published a research report on Gilead Sciences (NASDAQ: GILD) after the company announced that it has signed a licensing agreement with Boehringer Ingelheim to increase the development and commercialization of BI's HIV-treatment portfolio. In the report, Piper Jaffray writes, "We...
